Business Description
Calliditas Therapeutics AB
ISIN : SE0010441584
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.01 | |||||
Equity-to-Asset | 0.18 | |||||
Debt-to-Equity | 2.89 | |||||
Debt-to-EBITDA | -4.74 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.71 | |||||
Beneish M-Score | -1.79 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 957.8 | |||||
3-Year EBITDA Growth Rate | 13.5 | |||||
3-Year EPS without NRI Growth Rate | -2 | |||||
3-Year FCF Growth Rate | -6.6 | |||||
3-Year Book Growth Rate | -36.4 | |||||
Future 3-5Y Total Revenue Growth Rate | 57.2 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 54.79 | |||||
9-Day RSI | 52.03 | |||||
14-Day RSI | 49.17 | |||||
6-1 Month Momentum % | 22.11 | |||||
12-1 Month Momentum % | -10.87 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.13 | |||||
Quick Ratio | 3.08 | |||||
Cash Ratio | 2.39 | |||||
Days Inventory | 102.5 | |||||
Days Sales Outstanding | 48.21 | |||||
Days Payable | 709.94 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -6.37 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 94.94 | |||||
Operating Margin % | -22.58 | |||||
Net Margin % | -27.44 | |||||
FCF Margin % | -19.96 | |||||
ROE % | -56.93 | |||||
ROA % | -15.63 | |||||
ROIC % | -42.51 | |||||
ROC (Joel Greenblatt) % | -444.94 | |||||
ROCE % | -14.13 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 769.23 | |||||
PS Ratio | 5.63 | |||||
PB Ratio | 17.09 | |||||
EV-to-EBIT | -28.05 | |||||
EV-to-Forward-EBIT | 72.18 | |||||
EV-to-EBITDA | -28.05 | |||||
EV-to-Forward-EBITDA | 72.18 | |||||
EV-to-Revenue | 5.63 | |||||
EV-to-Forward-Revenue | 2.98 | |||||
EV-to-FCF | -28.74 | |||||
Earnings Yield (Greenblatt) % | -3.57 | |||||
FCF Yield % | -3.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Calliditas Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 1,015.537 | ||
EPS (TTM) (kr) | -5.19 | ||
Beta | 1.17 | ||
Volatility % | 53.3 | ||
14-Day RSI | 49.17 | ||
14-Day ATR (kr) | 4.13581 | ||
20-Day SMA (kr) | 105.55 | ||
12-1 Month Momentum % | -10.87 | ||
52-Week Range (kr) | 80.8 - 141.9 | ||
Shares Outstanding (Mil) | 53.67 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Calliditas Therapeutics AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Calliditas Therapeutics AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Calliditas Therapeutics AB Frequently Asked Questions
What is Calliditas Therapeutics AB(OSTO:CALTX)'s stock price today?
When is next earnings date of Calliditas Therapeutics AB(OSTO:CALTX)?
Does Calliditas Therapeutics AB(OSTO:CALTX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |